Clinical trial
A Double-blind, Randomized, Placebo-controlled, Single-dose Escalation and Multi-dose Escalation Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism, Along With a Single-arm Study Assessing the Long-term Efficacy and Safety of MT1013
NCT06747247 is registered in ClinicalTrials.gov with Shaanxi Micot Pharmaceutical Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Single-dose Escalation and Multi-dose Escalation Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism, Along With a Single-arm Study Assessing the Long-term Efficacy and Safety of MT1013
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 7, 2023
- Completion date
- May 12, 2025
- Enrollment
- 98 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
secondary hyperparathyroidism (shpt) in subjects with chronic kidney disease (ckd) on hemodialysis